Rep. Thomas H. Kean Jr discloses trade(s) in ABT, ESAB, JNJ, MDLZ, SYK
Thomas H. Kean Jr (NJ07) disclosed 6 transactions, traded Sep 17 – Sep 30: 2 purchases and 4 sales.
| Traded | Ticker | Company | Action | Amount | Owner |
|---|---|---|---|---|---|
| Sep 30 | JNJ | Kean Family Partnership Johnson & Johnson | Sell (partial) | $1,001 - $15,000 | Self |
| Sep 30 | SYK | Kean Family Partnership Stryker Corporation | Sell (partial) | $1,001 - $15,000 | Self |
| Sep 29 | ESAB | Kean Family Partnership ESAB Corporation | Buy | $1,001 - $15,000 | Self |
| Sep 23 | MDLZ | State Street Bank & Trust Co. Mondelez International, Inc. | Sell (partial) | $1,001 - $15,000 | Self |
| Sep 17 | ABT | Abbott Laboratories | Sell (partial) | $1,001 - $15,000 | Self |
| Sep 17 | TXN | State Street Bank & Trust Co. Texas Instruments Incorporated | Buy | $1,001 - $15,000 | Self |
ORIGINAL FILING ↗ALL FILINGS BY THOMAS H. KEAN JR →CONGRESS TRADES DASHBOARD →
Amounts are the ranges members report. Rows are read automatically from the filing; a trade split across a page break can be missed, so the original filing is the full record.
What This Means
A U.S. House member filed routine financial disclosures covering equity transactions in Abbott Laboratories, ESAB Corporation, Johnson & Johnson, Mondelez International, and Stryker Corporation. Congressional stock trading disclosures are public record and subject to the STOCK Act, which prohibits trading on material nonpublic information obtained through official duties. The trades themselves carry no inherent market signal absent evidence of timing tied to legislative action or insider information.
Sources (1)
Every claim below links directly to the original reporting it was drawn from. Penblock synthesizes and cross-references these sources — it doesn't originate the reporting.
- Thomas H. Kean JrNov 3, 2026View the original filing at the House Clerk ↗
How This Could Play Out
First assessed Nov 3
Resolved
UNLIKELYNo market impact; routine disclosure filing carries no actionable signal on underlying equities.
Status quo
LIKELYNo market impact; disclosure remains a compliance record absent evidence of timing correlation with legislative action or material nonpublic information.
Worsens
POSSIBLEAffected equities face selling pressure if investigation reveals trades timed to undisclosed legislative developments or committee information.
SPONSORED
More on Congressional Stock Trading
- Rep. Donald Sternoff Beyer Jr files a Periodic Transaction ReportNov 1
- Rep. John J Mr McGuire III discloses trade(s) in AVGO, MUNov 1
- Rep. Carol Devine Miller discloses trade(s) in HONAOct 30
- Rep. David J. Taylor discloses trade(s) in T, LRCX, MPC, PLD, RPMOct 29
- Rep. Suzan K. DelBene files a Periodic Transaction ReportOct 28
- Rep. Kevin Hern discloses trade(s) in ASML, STX, TXNOct 28
Get the market digest by email
One email each morning: yesterday's key story and what it means for markets. Free.